Kelly Sanderson Schrems succeeds steve hopkinson as AbbVie UK GM.

{
  "signal_id": "5f169eeb-1f19-4a83-90de-77f62ce544b8",
  "signal_type": "news",
  "signal_subtype": "hires",
  "detected_at": "2026-05-15T00:00:00+00:00",
  "company": {
    "name": "AbbVie",
    "domain": "abbvie.com"
  },
  "data": {
    "url": "https://www.thepharmaletter.com/pharma-news/kelly-sanderson-schrems-succeeds-steve-hopkinson-as-abbvie-uk-gm",
    "title": "Kelly Sanderson Schrems succeeds steve hopkinson as AbbVie UK GM.",
    "ticker": "NYSE:ABBV",
    "contact": "Kelly Sanderson Schrems",
    "excerpt": "Kelly Sanderson Schrems succeeds steve hopkinson as AbbVie UK GM.\n\n15 May 2026\n\nUS drugmaker AbbVie (NYSE: ABBV) has announced that Kelly Sanderson Schrems (pictured, above) has been appointed as vice president and general manager, UK.\n\nThis article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.\n\nTry before you buy\n\nFree.\n\n7 day trial access\n\n* All the news that moves the needle in pharma and biotech\n* Exclusive features, podcasts, interviews, data analyses and commentary from its global network of life sciences reporters.\n* Receive The Pharma Letter daily news bulletin, free forever.\n\nBecome a subscriber\n\n£820.\n\nOr £77 per month\n\n* Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.\n* Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.\n* Daily roundup of key events in pharma and biotech.\n* Monthly in-depth briefings on Boardroom appointments and M&A news.\n* Choose from a cost-effective annual package or a...",
    "summary": "AbbVie hires Kelly Sanderson Schrems as vice president and general manager, UK.",
    "location": "United States, Northern America, Americas",
    "planning": false,
    "image_url": "https://cdn.thepharmaletter.com/convert/files/2026/05/b7341490-5077-11f1-b850-110329f5daf5-Kelly%20Sanderson%20Large.jpg/r%5Bwidth%5D=1280/b7341490-5077-11f1-b850-110329f5daf5-Kelly%20Sanderson%20Large.jpg",
    "job_title": "vice president and general manager, UK",
    "confidence": 0.3773,
    "published_at": "2026-05-15T00:00:00Z",
    "location_data": [
      {
        "region": "Northern America",
        "country": "United States",
        "continent": "Americas",
        "fuzzy_match": false
      }
    ],
    "job_title_tags": [
      "directors",
      "management"
    ],
    "article_sentence": "US drugmaker AbbVie (NYSE: ABBV) has announced that Kelly Sanderson Schrems (pictured, above) has been appointed as vice president and general manager, UK."
  }
}

curl https://signals.autobound.ai/v1/signals/5f169eeb-1f19-4a83-90de-77f62ce544b8 \
  -H "X-API-KEY: $AUTOBOUND_API_KEY"

curl -X POST https://signals.autobound.ai/v1/companies/enrich \
  -H "X-API-KEY: $AUTOBOUND_API_KEY" \
  -H "Content-Type: application/json" \
  -d '{"domain":"abbvie.com","limit":20}'